PEPG (PepGen Inc.) EV/EBITDA Multiple
This price visualization for PepGen Inc. (PEPG), which specializes in muscle pathology therapies and assists in the basic valuation of the asset, demonstrates the 0.00 indicator. The business relies on external contractors for drug production and testing, thereby minimizing its own capacities. Operational stability is ensured by the global distribution of raw material suppliers, which prevents any disruptions in the supply chains of biocomponent for laboratories.
Comprehensive metric breakdowns and analytics for pepgen.com (PEPG)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- debt and liquidity details:
Total Debt to Equity Ratio PepGen Inc.|PEPG - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital PepGen|PEPG - Company Total Debt Obligations|Debt to Book Capitalization Ratio PepGen Inc.|PEPG - Company Long-Term Indebtedness|Company Short-Term Debts PepGen|Quick Liquidity Indicator pepgen.com
- financial results and valuation multiples details:
PEPG - Net Financial Result|Expected Profit PepGen Inc.|PEPG - Market Cap to Net Income|Forward P/E Multiple PepGen|PEPG - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc.|PEPG - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) PepGen|PEPG - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months pepgen.com|PEPG - Earnings per share growth this year|Earnings growth forecast for next year PepGen Inc.
Comprehensive company analysis:PEPG (PepGen Corp)
The multiple combines market capitalization and net debt, comparing the total enterprise value with operating profit before depreciation and amortization to determine the real value of the business. For PepGen Inc. (PEPG), with its closed patent loop of the EDO platform, the current EV/EBITDA multiple reflects the market valuation of RNA therapy potential relative to current efficiency, where a downward trend on the chart signals an undervaluation of biopharmaceutical assets.
Competitor analysis for PepGen Inc.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX (Neurocrine Corp) - Company Value to Operating Income Before Depreciation Ratio|Regencell Bioscience - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple axsome.com (AXSM)|ACAD: EV/EBITDA Multiple|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus Corp)|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Biohaven Ltd (BHVN)|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVI (Trevi Corp) - Enterprise Value to Operating Income Before Depreciation|PRAX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio anavex.com|Enterprise Value to EBITDA Ratio CBLL|Prothena Corporation PLC (PRTA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OMER (Omeros)|neurogene.com (NGNE) - Company Value to EBITDA|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Scilex Holding Company, Inc. SCLX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tevogen Bio Holdings|Enterprise Value to Operating Income Before Depreciation ACOG (Alpha Cognition Corp)|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|Cassava - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Assertio Holdings ASRT|COYA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VTGN (Vistagen Therapeutics)|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Acumen Pharmaceuticals Inc. (ABOS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Alterity Therapeutics Ltd - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|JUNS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|ANVS (Annovis Bio Inc) - Company Value to Operating Income Before Depreciation Ratio|Grace Tx - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Firefly Neuro (AIFF)|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|Enterprise Value to Operating Income Before Depreciation MTVA (MetaVia, Inc.)|Enterprise Value to EBITDA Ratio NRXS (NeurAxis, Inc)|HSDT (heliusmedical.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|Total Company Value to Operating Income Before Depreciation Ratio Neuphoria Therapeutics, Inc. (NEUP)|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATHA (Athira Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|ADXN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Alzamend Neuro|Enterprise Value to EBITDA Ratio CYCN|Protagenic (PTIX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|BrainStorm Cell Therapeutics Inc. (BCLI) - Company Value to EBITDA|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CHRO|ELYM: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Intra-Cellular Therapies, Inc. ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Enterprise Value to Operating Income Before Depreciation MRNS (Marinus Pharma)|EV/EBITDA Multiple NKGN|NRBO - Company Value to EBITDA|Sage Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA cerevel.com (CERE)
